# Phase 2 prostatic cancer trials recruiting: 213 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 213 trials in phase 2 for prostatic cancer that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 prostatic cancer trials: 213 rows for $10.65, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 5 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/prostatic-neoplasms

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 213
- Recruiting or not yet: 213
- Read on: November 19, 2026

## Trials

The 25 newest of 213, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 9, 2026 | NCT07925268 | Study of Ifinatamab Deruxtecan in De Novo or Treatment-Emergent Neuroendocrine Prostate Cancer | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Neuroendocrine Prostate Cancer (NEPC), Metastatic Prostate Adenocarcinoma, Prostate Cancer | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07925268) |
| November 9, 2026 | NCT07924605 | PSMA PET/MRI for Predicting and Detecting Prostate Cancer | University of Wisconsin, Madison | Phase 2 | Not yet recruiting | Prostate Cancer, High-Risk Localized Prostate Cancer, Locally Advanced Prostate Cancer, Low-Risk Prostate Cancer... | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07924605) |
| November 4, 2026 | NCT07914855 | Testing the Anti-cancer Drug DSP-5336 (Enzomenib) in Prostate Cancer | National Cancer Institute (NCI) | Phase 2 | Not yet recruiting | Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07914855) |
| October 30, 2026 | NCT07907653 | Deutenzalutamide and Hormone Therapy Before and After Surgery With Docetaxel Before Surgery for High-Risk Localized or Locally Advanced... | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 2 | Not yet recruiting | Prostate Cancer (Adenocarcinoma) | 37 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07907653) |
| October 29, 2026 | NCT07904026 | Testosterone-Informed De-Escalation in Metastatic Prostate Cancer (TIDE PC) | University of Nebraska | Phase 2 | Not yet recruiting | Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07904026) |
| October 20, 2026 | NCT07882862 | HRT-PC Trial: Hormone Recovery After Treatment for Prostate Cancer Trial. An Open-label Phase II Study of Clomiphene Citrate in Patients... | University of Nebraska | Phase 2 | Not yet recruiting | Prostate Cancer | 83 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07882862) |
| October 13, 2026 | NCT07871110 | Safety, Efficacy and Pharmacokinetics of TT00420 Tablets Combined With Novel Endocrine Therapy in Patients With Metastatic... | TransThera Sciences (Nanjing), Inc. | Phase 2 | Recruiting | Prostate Cancer (CRPC) | 182 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07871110) |
| October 9, 2026 | NCT07867158 | Study of Boswellia for Urinary Toxicity in Prostate Cancer Radiotherapy | Brigham and Women's Hospital | Phase 2 | Not yet recruiting | Prostate Cancer | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07867158) |
| October 6, 2026 | NCT07860554 | Pluvicto for the Treatment of African American Men With Metastatic Castration-Resistant Prostate Cancer | Emory University | Phase 2 | Not yet recruiting | Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | 88 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07860554) |
| October 6, 2026 | NCT07860047 | Multi-peptide Vaccination and Bispecific PSMAxCD3 Antibody Treatment in Patients With Prostate Cancer | University Hospital Tuebingen | Phase 2 | Recruiting | Prostate Cancer | 84 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07860047) |
| September 24, 2026 | NCT07838753 | A Study Testing if Patients With Advanced Prostate Cancer Who Are Responding Well to Combination Treatment Can Safely Reduce Their... | Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute | Phase 2 | Not yet recruiting | Castration Sensitive Prostate Cancer, Metastatic Prostate Cancer | 170 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07838753) |
| September 21, 2026 | NCT07832292 | A Study of JNJ-101556143 in Participants With Metastatic Prostate Cancer | Janssen Research & Development, LLC | Phase 2 | Recruiting | Prostatic Neoplasms | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07832292) |
| September 21, 2026 | NCT07830212 | Diagnostic Performance of ACP3-Targeted PET Imaging in Patients With Primary and Recurrent Prostate Cancer: An Open-Label, Single-Arm... | Sponsor not shown (see the record) | Phase 2 | Recruiting | Prostatic Neoplasms, Prostate Cancer | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07830212) |
| September 8, 2026 | NCT07807293 | Radioguided Salvage Pelvic Node Dissection in Oligometastatic Prostate Cancer - SALVAGE | University of British Columbia | Phase 2 | Not yet recruiting | Prostate Cancer, Oligometastatic | 62 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07807293) |
| September 3, 2026 | NCT07801664 | Short Course ADT for High Risk Low/Intermediate Risk ARTERA Prostate Cancer | NYU Langone Health | Phase 2 | Recruiting | Prostate Cancer | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07801664) |
| August 7, 2026 | NCT07751159 | Radiation Therapy Approaches for People With Prostate Cancer | Memorial Sloan Kettering Cancer Center | Phase 2 | Recruiting | Prostate Cancer Patients, Non-metastatic Prostate Cancer, High Risk Prostate Cancer | 126 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07751159) |
| August 4, 2026 | NCT07745361 | Study of Oral MRT-2359 With Apalutamide in Prostate Cancer | Monte Rosa Therapeutics, Inc | Phase 2 | Recruiting | Castration-Resistant Prostate Cancer (CRPC), Castration-Resistant Prostate Cancer, Prostate Cancer, Prostate Cancer... | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07745361) |
| July 30, 2026 | NCT07737925 | LuX: Xaluritamig in Participants With Metastatic Castrate Resistant Prostate Cancer and Suboptimal Response to Lutetium 177 Vipivotide... | Thomas Jefferson University | Phase 2 | Not yet recruiting | Prostate Cancer, Metastatic Castrate Resistant Prostate Cancer | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07737925) |
| July 29, 2026 | NCT07733908 | Effectiveness of Posluma PET Scan for Post-Treatment Monitoring of Prostate Cancer | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Prostate Cancer | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07733908) |
| July 28, 2026 | NCT07730151 | Efficacy and Safety of Darolutamide Combined With Docetaxel and ADT as Neoadjuvant Therapy for Locally Advanced Prostate Cancer. | RenJi Hospital | Phase 2 | Not yet recruiting | Prostate Cancer, Prostate, Prostate Cancer Patients | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07730151) |
| July 23, 2026 | NCT07723651 | \[18F\]Fluorthanatrace - Positron Emission Tomography (FTT-PET) and ctDNA to Predict Response to PARP Inhibitor Therapy in Metastatic... | Washington University School of Medicine | Phase 2 | Not yet recruiting | Metastatic Prostate Cancer, Prostate Cancer | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07723651) |
| July 21, 2026 | NCT07717268 | Fractionated Stereotactic Radiotherapy Plus Second-generation Antiandrogen for Oligometastatic Castration-resistant Prostate Cancer... | Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic | Phase 2 | Recruiting | Prostatic Neoplasms, Castration-Resistant | 51 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07717268) |
| July 21, 2026 | NCT07717099 | Radium-223 for High-Volume Metastatic Hormone Sensitive Prostate Cancer | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Metastatic Hormone-Sensitive Prostate Cance | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07717099) |
| July 17, 2026 | NCT07711314 | Adjuvant Rezvilutamide Monotherapy for High-Risk Prostate Cancer After Radical Prostatectomy | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Phase 2 | Recruiting | Prostate Cancer (Post Prostatectomy) | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07711314) |
| July 13, 2026 | NCT07698535 | Measuring Circulating Tumor Deoxyribonucleic Acid Tumor Fraction to Guide Early 177Lu-PSMA-617 Treatment Discontinuation in Patients With... | University of Washington | Phase 2 | Recruiting | Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07698535) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| National Cancer Institute (NCI) | 9 |
| University of Nebraska | 5 |
| City of Hope Medical Center | 5 |
| Mayo Clinic | 5 |
| Fudan University | 5 |
| The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 5 |
| VA Office of Research and Development | 4 |
| Memorial Sloan Kettering Cancer Center | 4 |
| University Health Network, Toronto | 4 |
| M.D. Anderson Cancer Center | 4 |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 4 |
| Jonsson Comprehensive Cancer Center | 4 |
| University of Washington | 3 |
| University of California, San Diego | 3 |
| Prostate Cancer Clinical Trials Consortium | 2 |
| German Oncology Center, Cyprus | 2 |
| Medical University of South Carolina | 2 |
| AHS Cancer Control Alberta | 2 |
| Cedars-Sinai Medical Center | 2 |
| Case Comprehensive Cancer Center | 2 |
| University of British Columbia | 2 |
| RenJi Hospital | 2 |
| Icahn School of Medicine at Mount Sinai | 2 |
| NYU Langone Health | 2 |
| Hoag Memorial Hospital Presbyterian | 2 |

## By country

| Country | Trials |
| --- | --- |
| United States | 128 |
| China | 31 |
| Canada | 15 |
| Germany | 6 |
| Australia | 6 |
| Spain | 6 |
| United Kingdom | 5 |
| Italy | 5 |
| Japan | 4 |
| Netherlands | 4 |
| France | 4 |
| South Korea | 3 |
| Cyprus | 2 |
| Belgium | 2 |
| Denmark | 2 |
| Sweden | 2 |
| Poland | 2 |
| Puerto Rico | 2 |
| Taiwan | 2 |
| Argentina | 2 |
| India | 2 |
| Austria | 2 |
| Turkey (Türkiye) | 1 |
| Ireland | 1 |
| Hong Kong | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Food and beverage distributors in the United States](https://specstream.ai/data/businesses/food-and-beverage-distributors/united-states)
- [Persian restaurants in the United States](https://specstream.ai/data/businesses/persian-restaurants/united-states)
- [African restaurants in the United States](https://specstream.ai/data/businesses/african-restaurants/united-states)
- [Electricians in the United States](https://specstream.ai/data/businesses/electricians/united-states)
- [Motels in the United States](https://specstream.ai/data/businesses/motels/united-states)
- [Ukrainian restaurants in the United States](https://specstream.ai/data/businesses/ukrainian-restaurants/united-states)
